Correction: Development of hollow ferrogadolinium nanonetworks for dual-modal MRI guided cancer chemotherapy

Ting Tang^{1

2}, Xiao Sun³, Xuedong Xu⁴, Yifeng Bian¹, Xiaojie Ma¹, Ning Chen¹

Affiliations

¹ Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University Nanjing 210029 China dentistchenning@126.com.
² Department of Dental Implantology, Hefei Stomatology Hospital, Clinical School of Anhui Medical University Hefei 230001 China.
³ Department of Chemical and Biomolecular Engineering, National University of Singapore Singapore 117585 Singapore xiaosun8000@163.com.
⁴ China Shijiazhuang Pharmaceutical Group Co., Ltd. Shijiazhuang 050038 China.

Published Erratum

Ting Tang et al. RSC Adv. 2019.

. 2019 Mar 5;9(13):7277.

doi: 10.1039/c9ra90017a. eCollection 2019 Mar 1.

Ting Tang^{1

2}, Xiao Sun³, Xuedong Xu⁴, Yifeng Bian¹, Xiaojie Ma¹, Ning Chen¹

¹ Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University Nanjing 210029 China dentistchenning@126.com.
² Department of Dental Implantology, Hefei Stomatology Hospital, Clinical School of Anhui Medical University Hefei 230001 China.
³ Department of Chemical and Biomolecular Engineering, National University of Singapore Singapore 117585 Singapore xiaosun8000@163.com.
⁴ China Shijiazhuang Pharmaceutical Group Co., Ltd. Shijiazhuang 050038 China.

Abstract

[This corrects the article DOI: 10.1039/C8RA09102A.].

This journal is © The Royal Society of Chemistry.

Development of hollow ferrogadolinium nanonetworks for dual-modal MRI guided cancer chemotherapy.
Tang T, Sun X, Xu X, Bian Y, Ma X, Chen N. Tang T, et al. RSC Adv. 2019 Jan 18;9(5):2559-2566. doi: 10.1039/c8ra09102a. eCollection 2019 Jan 18. RSC Adv. 2019. PMID: 35520519 Free PMC article.